Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowed)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website Save this grant

Next deadline: Jun 30, 2024 (Letter of inquiry)

Later deadlines: Jul 30, 2024 (Full proposal)

Grant amount: Unspecified amount

Fields of work: HIV/AIDS Vaccines

Applicant type: Organizations

Funding uses: Research

Location of project: Anywhere in the world

Location of residency: Anywhere in the world

Overview:

NOTE: 

  • Letter of Inquiry (Letter of Intent) - This is due 30 days prior to the application due date (due by 5:00 pm local time of applicant organization).
  • The following deadline applies to the AIDS-related grant application (due by 5:00 pm local time of applicant organization): 
    • July 30, 2024

Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowed)

The purpose of this Notice of Funding Opportunity (NOFO) is to support product-focused research to advance controlled release vaccine strategies to improve immune responses for HIV prevention, treatment, and cure and develop simplified or single-shot vaccination formulations. Timelines with measurable milestones are required. 

Research Scope and Objectives

The purpose of this Notice of Funding Opportunity (NOFO) is to support research to advance controlled-release strategies for HIV vaccines that aim to elicit protective and durable broadly neutralizing responses and antiviral T-cell/innate responses. Given recent advances in bioengineering and immunology, it is timely to investigate delivery approaches for controlled HIV vaccine release while the HIV field is developing immunogens. Proposed projects may be early or later in product development. Depending on the stage of product development, applications should propose strategies to:

  • establish proof-of-principle,
  • optimize approaches in small animal models,
  • show maintenance of vaccine structure and bioactivity throughout the delivery period,
  • evaluate feasibility for GMP manufacturing, and
  • study the safety of the optimized delivery strategy.

Proof-of-principle studies should include an assessment of immunogenicity and preliminary efficacy in a relevant animal model against a robust benchmark.

Projects will necessitate collaborative cross-disciplinary teams, including experts in immunology, product development and behavioral scientists, as applicable. Applications must include significant involvement of a translational partner with product development expertise to address the considerable manufacturing challenges. Investigation and inclusion of product end-user preferences throughout product development is highly encouraged, including the involvement of a behavioral scientist.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

US Dept. of Health & Human Services: National Institutes of Health (NIH)
FUNDER

Your history with this funder
0
SAVED OPPORTUNITIES
No saved opportunities from this funder yet
FUNDER NOTES
Save this opportunity to add notes...
CONTACTS
Save this opportunity to add contacts...

Other Funding Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

Forecasted Funding Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih) help icon

Find funders like US Dept. of Health & Human Services: National Institutes of Health (NIH)

See funders proven to support nonprofits like yours.

No credit card required.
instrumentl testimonial face

"Winning 30% more grants thanks to Instrumentl was a huge morale boost. My confidence continues to grow."

Linda Rucker, Grant Writer

This page was last reviewed March 28, 2024 and last updated March 28, 2024